> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bexion Wins Orphan Status for Pediatric Glioma Drug
- URL: https://www.fdaweb.com/bexion-wins-orphan-status-for-pediatric-glioma-drug/
- Published: 2020-05-07T12:00:00.000Z
- Updated: 2026-09-14T16:14:13.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146739

FDA has granted Bexion Pharmaceuticals an orphan drug designation for BXQ-350 and its use for treating malignant glioma, including diffuse intrinsic pontine glioma (DIPG), which primarily affects children. The company says DIPG makes up 10-15% of all brain tumors in children, with about 150-300 new diagnoses per year in the U.S. It describes the therapy as a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine.

“BXQ-350 has demonstrated pre-clinical antitumor effects in vitro and in vivo, particularly in brain and other solid tumors, including those that may lead to brain metastases,” Bexion says, adding that it has completed a multi-site first-in-human Phase 1 clinical trial of BXQ-350 for solid tumors and gliomas, and a Phase 1 pediatric trial completed enrollment in late 2019.